Betaferon still works: A new ray of hope for the injectables?

Over the last 5 years, the therapy for RRMS has radically changed.  Oral therapies have come to the fore, leaving the injectables a “not so flavor of the month”.  In this months issue of JNNP the BENEFITS study group reports on utility of betaferon in CIS.  The time to second relapse was significantly longer when treated with betaferons.

 

Read more at:

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

Open AccessPatient's Choice

  1. G Edan1,
  2. L Kappos2,
  3. X Montalbán3,
  4. C H Polman4,
  5. M S Freedman5,
  6. H-P Hartung6,
  7. D Miller7,
  8. F Barkhof8,
  9. J Herrmann9,
  10. V Lanius10,
  11. B Stemper10,
  12. C Pohl10,11,
  13. R Sandbrink6,10,
  14. D Pleimes12
  15. for the BENEFIT Study Group

J Neurol Neurosurg Psychiatry 2014;85:1183-1189 doi:10.1136/jnnp-2013-306222